LAS VEGAS, Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioAdaptives Inc. (OTC: BDPT) ushered in a new direction by appointing James Keener as CEO on May 21, 2024. Previous management retired, and Keener began ...

NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or the “Company”) today announced that on November 21 2024, it received written notice (the “Delisting Notice”) from The Nasdaq Stock Market LLC ...

Paulson Investment Company, LLC is acting as the exclusive placement agent in connection with the offering.

CAMBRIDGE, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that Eric Shaff, President and Chief Executive ...

THE WOODLANDS, Texas, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the company has made the strategic decision to eliminate its commercial ...

“We are grateful to Avenue Capital for the support they have demonstrated during this challenging time,” stated Michael Rowe, Chief Executive Officer of Eyenovia. “We took immediate steps to ...

For further information in relation to the AGM, shareholders should refer to the Notice of Annual General Meeting and the AGM Letter which have been despatched to shareholders. Copies of these ...

The full text of, inter alia, the resolutions proposed and passed at the Annual General Meeting and General Meeting can be found in the Notice of the General Meeting on the Company's website at: https ...

The closing of the Offering is expected to occur on or about November 25, 2024, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from this ...

PALO ALTO, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and ...

NEW HAVEN, Conn., Nov. 22, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop ...

G&A expenses remain stable at around CHF 1.9 million for both nine-month period ended September 30, 2024 and 2023. G&A expenses decreased by CHF 0.1 million to CHF 0.5 million during the third quarter ...